BOSTON, June 1, 2026
Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for povetacicept, an investigational dual BAFF/APRIL inhibitor for adults with IgA nephropathy (IgAN). The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026, bringing the therapy one step closer to potential approval. If approved, povetacicept would become the first commercialized product in Vertex’s growing nephrology franchise and could provide a new treatment option for patients living with this serious progressive kidney disease..
Phase 3 RAINIER Trial Delivers Strong Efficacy Results
The regulatory submission is supported by positive interim results from the ongoing Phase 3 RAINIER trial, the largest clinical study ever conducted in IgA nephropathy. The study met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction from baseline in urine protein-to-creatinine ratio (UPCR) at Week 36. Compared with placebo, the treatment demonstrated a 49.8% statistically significant reduction in proteinuria (P<0.0001), a key indicator of kidney disease progression. The benefits were consistent across all pre-specified patient subgroups, reinforcing the therapy’s potential as a best-in-class treatment for IgAN.
Secondary Endpoints Highlight Broad Clinical Benefits
Beyond reducing proteinuria, povetacicept achieved significant improvements across multiple secondary endpoints. Patients treated with the therapy experienced a 77.4% reduction in serum galactose-deficient IgA1 (Gd-IgA1), compared with a 9.1% increase in the placebo group, resulting in a 79.3% advantage versus placebo. Among patients with baseline hematuria, 85.1% achieved hematuria resolution, compared with only 23.4% in the placebo arm. These findings suggest that povetacicept may address several underlying disease mechanisms while delivering meaningful clinical benefits for patients with IgAN.
Advertisement
Favorable Safety Profile Supports Potential Approval
Povetacicept was generally safe and well tolerated, with most adverse events reported as mild to moderate in severity. No treatment-related serious adverse events were observed during the interim analysis. Although anti-drug antibodies were detected, they did not impact efficacy or safety outcomes. If approved, Vertex plans to launch povetacicept as a once-every-four-weeks low-volume subcutaneous auto-injector, allowing patients to administer treatment at home. The FDA acceptance marks an important milestone for Vertex as it expands beyond its established portfolio and advances innovative therapies for kidney and autoimmune diseases.
Source: Vertex Pharmaceuticals press release
